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BACKGROUND
Available data on the characteristics of patients with Ebola virus disease (EVD) and clini-
cal management of EVD in settings outside West Africa, as well as the complications 
observed in those patients, are limited.
METHODS
We reviewed available clinical, laboratory, and virologic data from all patients with labo-
ratory-confirmed Ebola virus infection who received care in U.S. and European hospitals 
from August 2014 through December 2015.
RESULTS
A total of 27 patients (median age, 36 years [range, 25 to 75]) with EVD received care; 19 
patients (70%) were male, 9 of 26 patients (35%) had coexisting conditions, and 22 (81%) 
were health care personnel. Of the 27 patients, 24 (89%) were medically evacuated from 
West Africa or were exposed to and infected with Ebola virus in West Africa and had onset 
of illness and laboratory confirmation of Ebola virus infection in Europe or the United 
States, and 3 (11%) acquired EVD in the United States or Europe. At the onset of illness, 
the most common signs and symptoms were fatigue (20 patients [80%]) and fever or fe-
verishness (17 patients [68%]). During the clinical course, the predominant findings in-
cluded diarrhea, hypoalbuminemia, hyponatremia, hypokalemia, hypocalcemia, and hypo-
magnesemia; 14 patients (52%) had hypoxemia, and 9 (33%) had oliguria, of whom 5 had 
anuria. Aminotransferase levels peaked at a median of 9 days after the onset of illness. 
Nearly all the patients received intravenous fluids and electrolyte supplementation; 9 (33%) 
received noninvasive or invasive mechanical ventilation; 5 (19%) received continuous renal-
replacement therapy; 22 (81%) received empirical antibiotics; and 23 (85%) received inves-
tigational therapies (19 [70%] received at least two experimental interventions). Ebola viral 
RNA levels in blood peaked at a median of 7 days after the onset of illness, and the median 
time from the onset of symptoms to clearance of viremia was 17.5 days. A total of 5 patients 
died, including 3 who had respiratory and renal failure, for a mortality of 18.5%.
CONCLUSIONS
Among the patients with EVD who were cared for in the United States or Europe, close 
monitoring and aggressive supportive care that included intravenous fluid hydration, correc-
tion of electrolyte abnormalities, nutritional support, and critical care management for respi-
ratory and renal failure were needed; 81.5% of these patients who received this care survived.
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The Ebola virus disease (EVD) epidemic in West Africa had resulted in more than 28,600 reported cases and more than 
11,300 deaths through December 2015; mortal-
ity reported for patients with EVD cared for in 
Ebola treatment units in West Africa has ranged 
from 37 to 74%.1-5 The provision of clinical care 
to patients with EVD in Ebola treatment units in 
West Africa has involved the need to balance 
many challenges, such as overwhelming num-
bers of severely ill patients, limited medical and 
nonmedical supplies, insufficient numbers of 
caregivers and resources, and hot and humid 
working conditions that limit the time that 
health care personnel in full personal protective 
equipment can attend to each patient.3,6,7 Thus, 
although most patients with EVD have received 
supportive care with oral rehydration solutions, 
antiemetic agents, analgesics, and antibiotics, 
not all Ebola treatment units have had intrave-
nous and electrolyte-replacement fluids available. 
It is believed that aggressive intravenous fluid 
hydration and correction of electrolyte abnor-
malities may improve the outcomes among se-
verely ill patients with EVD.3,5,7-9
Since early August 2014, several patients who 
received a diagnosis of EVD in West Africa were 
medically evacuated for care in higher-resource 
settings in Europe and the United States.10-16 In 
addition, a small number of patients received a 
diagnosis of EVD in Europe or the United States 
after they were infected by Ebola virus (EBOV) in 
West Africa or through nosocomial transmis-
sion in Europe or the United States.17,18 Begin-
ning in September 2014, conference calls among 
physicians in the United States and Europe who 
were caring for patients with EVD were held 
regularly — often weekly — to share detailed 
information and experiences in clinical care. 
Patients with EVD who were cared for in Europe 
and in the United States received close monitor-
ing of hemodynamic status, underwent extensive 
laboratory investigations, were provided support-
ive critical care management and nursing care, 
and were given the opportunity for treatment 
with investigational therapies that were not rou-
tinely available in Ebola treatment units in set-
tings with limited resources. In this report, we 
describe the clinical characteristics and clinical 
care of all the patients with EVD who were cared 
for in the United States and Europe.
Me thods
Study Design
Anonymized demographic, clinical, laboratory, 
and virologic data were collected retrospectively 
for all patients with confirmed EBOV infection 
who received treatment in the United States and 
Europe from August 2014 through December 
2015. All care and testing were clinically driven. 
Laboratory assays used in the care of patients 
with EVD are listed in the Methods section in 
the Supplementary Appendix, available with the 
full text of this article at NEJM.org. An Excel 
form was used as a standard data-collection tool 
by clinicians at each participating hospital. Data 
were uploaded through a secure server at the 
Centers for Disease Control and Prevention (CDC) 
and pooled for descriptive analyses.
Study Population
A patient with confirmed EVD was defined as an 
ill person with a blood, serum, or plasma speci-
men that tested positive on a reverse-transcrip-
tase–polymerase-chain-reaction (RT-PCR) assay 
that used primers and probes specific for EBOV. 
A medically evacuated patient with EVD was 
defined as a patient who had the onset of illness 
and laboratory confirmation of EBOV infection 
in West Africa and was then transported by air 
ambulance for care in Europe or the United 
States. A patient with an imported case of EVD 
was defined as a patient who had been exposed 
to and infected with EBOV in West Africa and 
had onset of illness and laboratory confirmation 
of EBOV infection in Europe or the United 
States. A locally acquired case was defined as a 
patient in whom exposure to EBOV, onset of ill-
ness, and laboratory confirmation of EBOV infec-
tion by RT-PCR occurred in Europe or the United 
States.
Study Oversight
This data-collection activity was determined to 
constitute a public health response not requiring 
institutional board review at the CDC. However, 
for some participating institutions, written in-
formed consent by the patient or the patient’s 
family was required and obtained for data collec-
tion. No specific funding was provided for this 
work. Clinical data for some of these patients 
with EVD have been published previously.10-16,18-20
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Statistical Analysis
Statistical significance was assessed with the 
use of Fisher’s exact test for binary values and a 
nonparametric two-sample test for median values 
equivalent to the Brown–Mood test; P values of 
less than 0.05 were considered to indicate statis-
tical significance, without correction for multi-
ple testing. Analyses were performed with the 
use of SAS statistical software, version 9.3 (SAS 
Institute), and Excel (Microsoft).
R esult s
Patients
A total of 27 patients with EVD received care in 
Europe or the United States at 15 hospitals in 
nine countries. Overall, the median age of the 
patients was 36 years (range, 25 to 75); 19 pa-
tients (70%) were male and 9 of 26 patients 
(35%) had coexisting conditions (Table S1 in the 
Supplementary Appendix). Twenty patients (74%; 
median age, 36.5 years) were medically evacuat-
ed from West Africa, and 3 patients (11%; median 
age, 29 years) were health care personnel who 
acquired EVD locally in the United States or 
Europe while caring for patients with EVD; in 
addition, there were 4 patients (15%; median age, 
38.5 years) with imported cases of EVD. A total 
of 22 patients (81%) were health care personnel, 
of whom 17 (77%) had worked in an Ebola treat-
ment unit in West Africa. Among the 27 patients 
with EVD, the median time from the onset of 
illness to the diagnosis of EVD was 3 days 
(range, 1 to 9), and the median time from the 
onset of illness to hospitalization was 4 days 
(range, 0 to 15) (Table S1 in the Supplementary 
Appendix). The median time from the onset of 
illness to hospitalization was 2 days among pa-
tients with imported cases and 4 days among 
both medically evacuated patients and patients 
with locally acquired cases.
Clinical Findings
At the time of the onset of illness, the most 
common sign or symptom reported was fatigue, 
which affected 20 patients (80%); fever or fever-
ishness was reported in 17 patients (68%). Other 
symptoms are shown in Figure 1A. By the time 
of admission to a hospital in Europe or the 
United States, most patients had fever, weakness, 
and gastrointestinal symptoms (Fig. 1B). Clini-
cal findings during hospitalization are summa-
rized in Table 1 and Table 2. Nearly half the 
patients had hypoxemia, with a median oxygen 
saturation of 84.5% while they were breathing 
ambient air, as measured by means of pulse 
oximetry. All the patients had diarrhea, with a 
median duration of 6 days and an estimated 
median maximum stool output of 3000 ml per 
24 hours (range, 100 to 10,000). A total of 33% 
had renal abnormalities, as manifested by oligu-
ria or anuria during the hospitalization. Sixteen 
patients (59%) received a clinical diagnosis of 
the systemic inflammatory response syndrome. 
Neurologic complications such as encephalopa-
thy or encephalitis were reported in one third of 
patients. A total of 9 patients (33%) had some 
evidence of bleeding (epistaxis, petechiae, melena, 
bloody diarrhea, or oozing around an intrave-
nous catheter site) at the time of hospital admis-
sion in the United States or Europe, and 14 
(52%) had oozing around an intravenous cathe-
ter site during hospitalization; however, gross 
hemorrhage was observed in only 2 patients 
(7%) at any time during hospitalization.
Laboratory Findings
Leukopenia was prominent in the first week of 
illness, with the nadir white-cell count at a me-
dian of 6 days after the onset of illness and the 
highest white-cell count at a median of 13 days 
after the onset of illness. Thrombocytopenia was 
reported in nearly all the patients. (Daily hema-
tologic values are shown in Figs. S1–S5 of the 
Supplementary Appendix.) Most patients had an 
elevated international normalized ratio during 
their hospitalization (median, 1.49) (Table S2 in 
the Supplementary Appendix). Aminotransferase 
levels peaked in the second week of illness; the 
median maximum aspartate aminotransferase 
level was more than three times the median 
maximum alanine aminotransferase level. Bili-
rubin levels, however, were only slightly elevated 
in most patients. Creatine kinase levels were 
markedly elevated in most patients tested, with 
a median maximum level of 1007.5 U per liter. 
Serum lactate levels were elevated in most pa-
tients who were tested, with a median maximum 
value of 2.8 mmol per liter. Five patients (19%) 
had elevated creatinine levels at admission, and 
11 patients (41%) had elevated creatinine levels 
at any time during hospitalization. Of those 
tested, the majority of patients with EVD had 
metabolic abnormalities that included hypona-
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tremia, hypokalemia, hypocalcemia, and hypo-
magnesemia, and all the patients had hypoalbu-
minemia during their hospitalization (Table 2).
Supportive Clinical Care
All patients received oral or intravenous electro-
lyte-replacement fluids to correct metabolic ab-
normalities. All but 1 patient received intrave-
nous fluids, and 15 patients (56%) received total 
parenteral nutrition. A total of 11 patients (41%) 
had a peripherally inserted central catheter, and 
18 (67%) had a central venous catheter placed 
(Table 1). Fluids were administered intravenous-
ly in 18 of 20 medically evacuated patients be-
fore their arrival in the United States or Europe, 
either initiated in West Africa or initiated during 
the evacuation flight. Antiemetics were given to 
most patients, but few received antidiarrheal 
medications (Table S3 in the Supplementary Ap-
pendix). A total of 22 patients (81%) received 
empirical antibiotic treatment with a median of 
2 antibiotics (range, 0 to 7), the most common 
of which was a third-generation cephalosporin. 
Of the 24 patients with EVD who had been in 
West Africa, 17 received antimalarial prophy-
laxis or treatment (or both) during their illness; 
of 14 patients who received antimalarial prophy-
laxis or treatment in West Africa, 1 had con-
firmed malaria. Of 8 patients who were treated 
for malaria in the United States or Europe, 2 had 
malaria that was confirmed by parasitologic 
testing. A total of 11 patients with EVD (41%) 
received nonconvalescent blood products, includ-
ing nonconvalescent whole blood in 4 patients, 
fresh-frozen plasma in 6 patients, and platelets 
in 5 patients.
Respiratory supportive care was provided fre-
quently; 19 patients (70%) received supplemental 
oxygen, of whom 9 (47%) had respiratory failure 
(Table 1). The median time from illness onset to 
respiratory failure was 9 days (range, 4 to 18). 
Four patients (15%) received noninvasive ventila-
tion, of whom 2 also received invasive mechani-
cal ventilation after noninvasive ventilation failed. 
Figure 1. Signs and Symptoms of Ebola Virus Disease 
Reported at the Onset of Illness and at Admission  
to a Hospital in Europe or the Unites States.
In Panel A, data were not available for all patients; the 
numbers in parentheses signify the numbers of patients 
with available data. In Panel B, data were available for 
all 27 patients for all signs and symptoms.
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Clinical Finding or Intervention*
Patients 
(N = 27)
no. (%)
Fever† 25 (93)
Pulmonary findings
Hypoxemia‡ 14 (52)
Pulmonary edema 12 (44)
Pneumonia 7 (26)
Respiratory failure 9 (33)
ARDS§ 6 (22)
Supplemental oxygen¶ 19 (70)
Noninvasive ventilation 4 (15)
Invasive mechanical ventilation 7 (26)
Renal findings
Oliguria (urine <500 ml/day) 9 (33)
Anuria (urine <100 ml/day) 5 (19)
Dialysis catheter 5 (19)
CRRT 5 (19)
Cardiac findings
Arrhythmia or electrocardiographic 
changes
11 (41)
Vasopressors or inotropes 8 (30)
Gastrointestinal findings
Diarrhea‖ 27 (100)
Vomiting 20 (74)
Ileus** 4 (15)
Intestinal paresis 4 (15)
Abdominal distention 10 (37)
Infectious findings
Sepsis†† 7 (26)
Septic shock†† 2 (7)
SIRS†† 16 (59)
Malaria‡‡ 2 (7)
Neurologic findings
Delirium§§ 9 (33)
Encephalopathy or encephalitis§§ 9 (33)
Seizures 1 (4)
Coma 3 (11)
Hematologic findings
Oozing from intravenous sites 14 (52)
Frank hemorrhage 2 (7)
Table 1. Clinical Findings and Interventions for 27 
Patients with Ebola Virus Disease during Hospitalization 
in the United States or Europe.
Clinical Finding or Intervention*
Patients 
(N = 27)
no. (%)
Intravenous access¶¶ 27 (100)
Peripherally inserted central catheter 11 (41)
Central venous catheter 18 (67)
Other intervention
Rectal tube 12 (44)
Indwelling urinary catheter 17 (63)
Critical illness‖‖ 11 (41)
Resuscitation attempt 2 (7)
*  Information on the median duration (range) of the clini-
cal finding or intervention was collected for only a small 
number of variables: fever, 7.5 days (1–16); noninvasive 
ventilation, 4 days (1–7); invasive mechanical ventilation, 
5 days (0.5–13); continuous renal-replacement therapy 
(CRRT), 4 days (2–28); diarrhea, 6 days (1–20); and 
vomiting, 2 days (1–27).
†  Fever was defined as a temperature higher than 38.0°C. 
The median temperature of the 27 patients at admission 
was 38.2°C (range, 34.6 to 40.4).
‡  The median minimum oxygen saturation while the pa-
tients were breathing ambient air was 84.5% (range, 65 
to 93) as measured by pulse oximetry.
§  Of the 9 patients with respiratory failure, 6 received a 
clinical diagnosis of the acute respiratory distress syn-
drome (ARDS), of whom 4 had concomitant pneumonia. 
One patient who received a clinical diagnosis of ARDS 
received supplemental oxygen without ventilatory sup-
port. Of the 4 patients with respiratory failure who did 
not receive a diagnosis of ARDS, 1 had pneumonia.
¶  Supplemental oxygen was delivered through a nasal can-
nula or face mask. Of the 4 patients who received non-
invasive ventilation, 2 subsequently received invasive 
mechanical ventilation after noninvasive ventilation failed.
‖  The median maximum volume of diarrhea per 24 hours 
was 3000 ml (range, 100 to 10,000).
**  Ileus was diagnosed by means of ultrasonography; none of 
the 4 patients with ileus had received antimotility agents.
††  Sepsis, septic shock, and the systemic inflammatory 
 response syndrome (SIRS) were diagnosed clinically;  
7 patients had both sepsis and SIRS reported, including 
the only patient with documented bacteremia.
‡‡  Cases of malaria were confirmed through parasitologic 
examination in the United States or Europe; at least  
1 additional patient had confirmed malaria that was 
treated in West Africa.
§§  Delirium and encephalopathy or encephalitis were diag-
nosed clinically; lumbar puncture and neuroimaging 
were not performed.
¶¶  The median maximum volume of intravenous fluid per 
24 hours was 4000 ml (range, 0 to 13,734). One patient 
had a peripheral intravenous catheter placed and received 
intravenous fluids in West Africa but not after medical 
evacuation.
‖‖  Critical illness was defined as illness that necessitated  
a patient’s receipt of noninvasive ventilation, invasive me-
chanical ventilation, CRRT, or vasopressors or inotropes.
Table 1. (Continued.)
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In total, 7 patients (26%) received invasive me-
chanical ventilation. Five of the 7 patients who 
received invasive mechanical ventilation also 
received continuous renal-replacement therapy; 
4 had been medically evacuated.
Investigational Therapies
Investigational therapies, which included immu-
notherapies (convalescent plasma or whole blood 
or triple monoclonal antibody cocktails [ZMapp, 
ZMab, or MIL77]) and products that had pre-
sumed antiviral activity (TKM-Ebola, favipiravir, 
brincidofovir, or amiodarone), or therapies that 
were administered to counteract vascular leak 
(FX06 or melanocortin) were administered to 23 
patients (85%) off-label or on a compassionate-
use basis (Table 3). Only patients in Europe re-
ceived ZMab, MIL77, favipiravir, FX06, or melano-
cortin. A total of 19 patients (70%) received at 
least two investigational therapies. A wide range 
of possible adverse effects was reported from 
these investigational therapies, such as the sys-
temic inflammatory response syndrome, hypoten-
sion, elevated aminotransferase levels, and trans-
fusion-associated acute lung injury (Table 3).
Results from Virologic and Immunologic 
Examination
At admission to a facility (mainly in the United 
States or Europe), the median RT-PCR cycle-
threshold value for detecting EBOV RNA was 24 
at a median of 5 days after the onset of illness 
(Table 4); for patients with available data on 
EBOV load, the median EBOV RNA level on ad-
mission was 2.7×107 copies per milliliter at a 
median of 6.5 days after the onset of illness. The 
median lowest cycle-threshold value was 21 at a 
median of 7 days after the onset of illness, and 
the median of the highest EBOV RNA level was 
7.3×107 copies per milliliter at a median of 7 days 
after the onset of illness. The median time from 
the onset of illness to the first negative RT-PCR 
assay result for EBOV RNA in a blood specimen 
was 17.5 days. (Daily EBOV levels in blood 
specimens are shown in Figs. S6 and S7 of the 
Supplementary Appendix.) EBOV RNA was de-
tected in saliva, sweat, stool, rectal swab, semen, 
vaginal, and skin swab specimens (Table S4 in 
the Supplementary Appendix). After the exclu-
sion of recipients of antibody-based immuno-
therapies (convalescent plasma, ZMapp, ZMab, 
and MIL77), IgM antibodies to EBOV were first 
detected in five patients at a median of 10 days 
(range, 6 to 11) after the onset of illness, and 
IgG antibodies to EBOV were first detected in 
six patients at a median of 11 days (range, 9 to 
11) after the onset of illness.
Outcomes
Overall, 5 patients with EVD died (mortality was 
11.1% after 14 days of illness and 18.5% after 28 
days of illness), 20 were discharged home, and 
2 were discharged to a rehabilitation facility 
(Table S5 in the Supplementary Appendix). The 
patients who died were older than the patients 
who survived (median age, 56 years [range, 42 to 
75] vs. 34.5 years [range, 25 to 59]; P = 0.01). 
Among the 5 critically ill patients who had mul-
tiorgan failure and received both invasive me-
chanical ventilation and continuous renal-re-
placement therapy, 3 died. The 2 patients who 
received only noninvasive ventilation survived. A 
total of 8 patients (30%), including the 5 patients 
who died, received vasopressors or inotropes. No 
patient received cardiopulmonary resuscitation; 
2 of the patients with fatal cases of EVD received 
resuscitation medications, and 1 of these pa-
tients also received transcutaneous pacing.
Patients who survived were hospitalized 
sooner after the onset of illness than were the 
patients who died (median, 3.5 days vs. 5 days; 
P = 0.03) (Table S1 in the Supplementary Appen-
dix). Among the medically evacuated patients, 
the median time from the onset of illness to 
initial hospitalization was shorter for the 16 pa-
tients who survived than for the 4 patients who 
died (4 days vs. 5 days, P = 0.02), as was the time 
from the onset of illness to hospital admission 
outside West Africa (6 days vs. 7.5 days, P = 0.03).
Among the patients with available data on 
creatinine and bilirubin levels at hospital admis-
sion in the United States or Europe, the propor-
tion of patients with elevated levels of creatinine 
(>1.3 mg per deciliter [115 μmol per liter]) was 
significantly higher among the patients who 
died than among the patients who survived (3 of 
5 patients vs. 2 of 22 patients, P = 0.03); similarly, 
the proportion of patients with elevated levels of 
bilirubin (>1.5 mg per deciliter [25.7 μmol per 
liter]) was significantly higher among the pa-
tients who died than among those who survived 
(2 of 5 patients vs. 0 of 17 patients, P = 0.04). The 
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initial median RT-PCR cycle-threshold value was 
lower, reflecting higher EBOV RNA levels, among 
the patients who died than among the patients 
who survived (21.2 vs. 24.9, P = 0.08), as was the 
median of the lowest RT-PCR cycle-threshold 
value anytime during the hospitalization (17.9 vs. 
22.8, P = 0.08), but these differences were not 
significant.
The median duration of hospitalization in 
Europe or the United States was 20 days among 
the patients who survived and 7 days among the 
patients who died. Among the patients who sur-
vived, the median time from illness onset to 
discharge was 28 days (range, 14 to 48), and 
among the patients who died, the median time 
from illness onset to death was 14 days (range, 
11 to 15). A high proportion of patients who 
survived had weakness, weight loss, anemia, and 
other laboratory abnormalities at the time of 
discharge (Table S5 in the Supplementary Ap-
pendix).
Discussion
The severity of disease among the patients with 
EVD who received care in Europe and the United 
States ranged from moderate to critical and fatal 
illness. Overall, mortality among those who 
were cared for in Europe or the United States 
was substantially lower (18.5%) than that among 
those who were cared for in Ebola treatment 
units in West Africa (37 to 74%).2-5 All 5 patients 
Abnormal Laboratory Result
At  
Admission
During  
Hospitalization
Treatment  
Received during  
Hospitalization†
no./total no. tested (%) no./total no. (%)
Hyponatremia (sodium <135 mmol/liter)‡ 12/27 (44) 21/27 (78) 21/21 (100)
Hypokalemia (potassium <3.5 mmol/liter) 10/27 (37) 18/27 (67) 18/18 (100)
Hypocalcemia (total calcium <8 mmol/liter) 10/16 (62) 15/20 (75) 10/15 (67)
Hypomagnesemia (magnesium <0.85 mmol/liter) 9/10 (90) 14/17 (82) 10/14 (71)
Hypoalbuminemia (albumin <3.5 g/dl) 20/25 (80) 25/25 (100) 7/25 (28)
Elevated creatinine (>1.3 mg/dl) 5/27 (19) 11/27 (41)
Elevated bilirubin (>1.5 mg/dl) 2/22 (9) 14/26 (54)
Elevated aspartate aminotransferase (>98 U/liter)§ 20/26 (77) 25/25 (100)
Elevated alanine aminotransferase (>110 U/liter)¶ 14/26 (54) 26/27 (96)
Leukocytosis (white-cell count ≥15,000/μl)‖ 3/25 (12) 17/27 (63)
Leukopenia (white-cell count <3500/μl)‖ 8/26 (31) 13/27 (48)
Neutropenia (absolute neutrophil count <1500/μl) 3/23 (13) 4/23 (17)
Lymphopenia (absolute lymphocyte count <1500/μl) 14/23 (61) 20/23 (87)
Anemia (hemoglobin <11 mg/dl)** 1/27 (4) 16/27 (59) 3/16 (19)
Thrombocytopenia (platelet count <150,000/μl) 22/26 (85) 26/27 (96) 5/26 (19)
Thrombocytosis (platelet count >450,000/μl)†† 0/26 9/27 (33) 2/9 (22)
*  To convert the values for calcium to milligrams per deciliter, divide by 0.25. To convert the values for magnesium to 
milligrams per deciliter, divide by 0.4114. To convert the values for creatinine to micromoles per liter, multiply by 88.4. 
To convert the values for bilirubin to micromoles per liter, multiply by 17.1.
†  Data are listed only for laboratory measures for which treatments were administered.
‡  Isotonic intravenous fluid administration was considered as treatment for hyponatremia.
§  Aspartate aminotransferase levels peaked at a median of 9 days after the onset of illness.
¶  Alanine aminotransferase levels peaked at a median of 9 days after the onset of illness.
‖  White-cell count was lowest at a median of 6 days after the onset of illness and peaked at a median of 13 days after 
the onset of illness.
**  Patients with anemia were treated with nonconvalescent whole blood or packed red-cell transfusion.
††  Patients with thrombocytosis were treated with low-molecular-weight heparin alone or with aspirin.
Table 2. Proportion of Patients with Abnormal Laboratory Values at Admission or at Any Time during Hospitalization  
in the United States or Europe.*
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who died were 42 years of age or older; in vari-
ous studies, age older than 40 years or older 
than 45 years has been identified as a risk factor 
in West Africa.2,21,22 The percentage of patients 
who died could have been as high as 41% (11 of 
27 patients), with up to six additional deaths, if 
advanced organ support had been unavailable 
for 2 survivors who received noninvasive ventila-
tion, 2 survivors who received invasive mechani-
cal ventilation, and 2 survivors who received both 
invasive mechanical ventilation and continuous 
renal-replacement therapy. A key feature of the 
clinical care of patients with EVD who were 
treated in Europe and the United States was the 
availability of laboratory testing to closely moni-
tor electrolyte levels and hematologic status. Our 
experience suggests that early presentation and 
receipt of supportive care, intravenous fluid re-
suscitation, careful fluid management and elec-
trolyte replacement to correct metabolic abnor-
malities, nutritional support, and critical care 
support may reduce mortality among patients 
with EVD.
A total of 5 patients had anuric renal failure 
and received continuous renal-replacement ther-
apy; the details regarding 3 of these patients 
have been published previously.11,12,16,23 Acute re-
nal failure could be caused by hypovolemic shock 
and acute tubular necrosis; EBOV infection of 
renal endothelial, interstitial, and tubular cells; 
or other factors.24 The high creatine kinase levels 
observed in most of the 27 patients with EVD we 
evaluated suggest that the elevated aspartate 
aminotransferase levels in most patients with 
EVD could originate from both hepatic and 
muscle sources, with rhabdomyolysis and myo-
globinuria also potentially contributing to renal 
injury.
Although EVD is not typically thought to have 
a clinically significant respiratory component, 
Investigational Therapy
Received at  
Least 1 Dose 
(N = 27)
Completed 
Course†
Adverse 
Reactions Suspected Adverse Reactions
number of patients (percent)
ZMapp or MIL77 8 (30) 2 (25) 4 (50) Fever, hypotension, agitation, tachycardia, 
tachypnea, flushing, palmar pruritus, rash
ZMab 5 (19) 1 (20) 2 (40) Fever, urticaria, serum sickness
TKM-Ebola 5 (19) 1 (20) 5 (100) Fever, chills, hypotension, the systemic inflam-
matory response syndrome, nausea, lipemia
Favipiravir 10 (37) 5 (50) 3 (30) Nausea, vomiting, elevated aspartate amino-
transferase, neutropenia, QTc prolongation
Brincidofovir 7 (26) 1 (14) 4 (57) Diarrhea, nausea, vomiting, elevated amino-
transferase levels, severe fatigue
FX06 2 (7) NA 0
Convalescent plasma‡ 10 (37) NA 3 (33) Transfusion-related acute lung injury
Convalescent whole blood 1 (4) NA 0
Amiodarone§ 2 (7) NA 1 (50) Bradycardia
Melanocortin 1 (4) NA 0
*  Among the 27 patients, 4 (15%) received no investigational therapies, 4 (15%) received one investigational therapy,  
12 (44%) received two investigational therapies, 5 (19%) received three investigational therapies, and 2 (7%) received 
four investigational therapies. NA denotes not applicable.
†  A complete course was defined as three doses for ZMapp, ZMab, and MIL77; as seven doses for TKM-Ebola; as five 
doses for brincidofovir; and as 7 days (twice daily) for favipiravir. However, the most effective dose and duration of 
 favipiravir treatment is unknown. There is no defined specific duration of treatment for amiodarone, FX06, melanocortin, 
convalescent plasma, or whole blood.
‡  The median dose of convalescent plasma was 525 ml (range, 200 to 1200); the median number of doses administered 
was 2 (range, 1 to 6).
§  Two patients received amiodarone for its presumed antiviral effect; one additional patient received amiodarone for 
treatment of an arrhythmia.
Table 3. Use of Investigational Therapies.*
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8 of the 27 patients (30%) we evaluated had cough 
at admission, a finding that is consistent with 
previous observations.21 Difficulty breathing at 
admission was associated with a fatal outcome 
among patients with EVD in Guinea.22 Overall, 9 of 
the patients with EVD (33%) who were cared for 
in the United States or Europe received noninva-
sive ventilation or invasive mechanical ventila-
tion for respiratory failure. The 2 patients with 
EVD who received noninvasive ventilation alone 
survived; however, of the 7 patients who received 
invasive mechanical ventilation, the 3 patients 
who also had renal failure that required continu-
ous renal-replacement therapy died. The patho-
physiological mechanism of pulmonary disease 
in patients with EVD is unknown, but there 
could be multiple contributing factors, including 
vascular leak from endothelial infection or cyto-
kine dysregulation or direct damage to EBOV-
infected cells. Evidence of replicating EBOV in 
alveolar macrophages and free EBOV in alveolar 
spaces has been reported in autopsy studies.24 
Among the patients with EVD who were cared 
for in Europe and the United States, other possi-
ble factors may contribute to pulmonary disease, 
such as aggressive intravenous fluid repletion or 
acute lung injury caused by or exacerbated by 
investigational therapies.15
Most patients with EVD who were cared for 
in the United States or Europe received investi-
gational therapies. Several patients had adverse 
events that were suspected to be related to the 
administration of these therapies. However, the 
clinical benefit as well as any harms associated 
with these experimental treatments cannot be 
independently assessed or distinguished from 
the supportive care administered because of their 
uncontrolled administration and because most 
patients received multiple, overlapping investiga-
tional therapies. In addition, it has been noted 
recently that the case-fatality proportion has been 
reduced over time in West Africa25; whether this 
may be a result of improvements in supportive 
care, observed reductions in EBOV RNA levels, 
or other factors is unknown. These issues argue 
against the use of historical controls and high-
light the need for well-designed controlled clini-
cal trials, including trials in settings that can 
provide critical care.
Our findings have several limitations. First, 
the number of patients with EVD who were 
treated in the United States and Europe was very 
small relative to the number of patients in West 
Africa, and the study was underpowered to de-
tect significant differences between fatal and 
nonfatal cases. Second, all the patients were 
adults, most were not African, and data on the 
medical care that was provided to medically 
evacuated patients while they were in West Af-
rica were limited. It is unknown whether recall 
bias regarding symptoms at the onset of illness 
was greater for medically evacuated patients 
who presented to medical care slightly later than 
patients with imported or locally acquired cases 
Variable
No. of 
Patients Value
No. of Days after 
Onset of Illness
median (range)
EBOV RNA level at admission
RT-PCR cycle-threshold value 19 24.0 (16.6–34.9)    5 (2–15)
EBOV RNA level — copies/ml 13 27×106 (0.114–1200×106)  6.5 (5–11)
Peak viral detection
Lowest RT-PCR cycle-threshold value 21 22.3 (13.2–39.5)    7 (2–15)
Highest EBOV RNA level — copies/ml 14 73×106 (0.5–2100×106)    7 (2–11)
Duration of viremia — days† 22 17.5 (5–27)
*  Virologic data from hospitalization in West Africa were unavailable for most medically evacuated patients; most results 
were from testing of blood specimens during hospitalization in the United States or Europe. EBOV denotes Ebola virus, 
and RT-PCR reverse-transcriptase–polymerase chain reaction.
†  The duration of viremia was calculated as the number of days from the onset of illness to the first negative RT-PCR re-
sult on a blood specimen.
Table 4. Results of Virologic Testing.*
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of EVD. Third, laboratories at participating sites 
used different RT-PCR assays to detect EBOV 
RNA, and therefore the cycle-threshold values 
and EBOV RNA levels were not comparable. 
Clinical laboratory testing was not performed 
systematically for all the patients, and the clini-
cal diagnoses of conditions, clinical manage-
ment, and decisions to use investigational thera-
pies were not standardized. Discharge criteria 
were not uniform at all clinical sites, and the 
most reliable testing indications for discharge 
among survivors remain uncertain.26 Fourth, al-
though most of the patients with EVD who were 
treated in Europe or the United States received 
investigational therapies, the clinical benefit of 
these uncontrolled interventions in addition to 
supportive management is unknown. Finally, 
given the retrospective nature of the collection 
of observational data without a comparison 
group and given the aforementioned limitations, 
our findings might not be generalizable to adult 
or pediatric patients with EVD in West Africa.
Although mortality due to EVD remains high, 
our findings indicate that close monitoring and 
aggressive supportive care, including intravenous 
fluid hydration, correction of electrolyte abnor-
malities, nutritional support, and critical care 
management for respiratory and renal failure, 
can improve survival among patients with EVD. 
Our findings also suggest that efforts should be 
made to improve the clinical care of patients 
with EVD in settings with limited resources, 
such as making certain that serum electrolyte 
levels and hematologic status can be closely 
monitored and intravenous fluid resuscitation 
and hydration, electrolyte replacement, and close 
supportive care can be provided, while ensuring 
adherence to recommended personal protective 
equipment and infection control precautions.
The views expressed in this article are those of the authors 
and do not necessarily represent the official position of the Cen-
ters for Disease Control and Prevention or the National Insti-
tutes of Health.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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